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Abstract
Background: Many commentators on ‘‘direct-to-consumer’’ genetic risk information have raised concerns that giving results
to individuals with insufficient knowledge and training in genomics may harm consumers, the health care system, and
society. In response, several commercial laboratories offering genomic risk profiling have shifted to more traditional ‘‘direct-
to-provider’’ (DTP) marketing strategies, repositioning clinicians as the intended recipients of advertising of laboratory
services and as gatekeepers to personal genomic information. Increasing popularity of next generation sequencing puts a
premium on ensuring that those who are charged with interpreting, translating, communicating and managing commercial
genomic risk information are appropriately equipped for the job. To shed light on their gatekeeping role, we conducted a
study to assess how and why early clinical users of genomic risk assessment incorporate these tools in their clinical practices
and how they interpret genomic information for their patients.
Methods and Findings: We conducted qualitative in-depth interviews with 18 clinicians providing genomic risk assessment
services to their patients in partnership with DNA Direct and Navigenics. Our findings suggest that clinicians learned most of
what they knew about genomics directly from the commercial laboratories. Clinicians rely on the expertise of the
commercial laboratories without the ability to critically evaluate the knowledge or assess risks.
Conclusions: DTP service delivery model cannot guarantee that providers will have adequate expertise or sound clinical
judgment. Even if clinicians want greater genomic knowledge, the current market structure is unlikely to build the
independent substantive expertise of clinicians, but rather promote its continued outsourcing. Because commercial
laboratories have the most ‘‘skin in the game’’ financially, genetics professionals and policymakers should scrutinize the
scientific validity and clinical soundness of the process by which these laboratories interpret their findings to assess whether
self-interested commercial sources are the most appropriate entities for gate-keeping genomic interpretation.
Citation: McGowan ML, Fishman JR, Settersten RA Jr, Lambrix MA, Juengst ET (2014) Gatekeepers or Intermediaries? The Role of Clinicians in Commercial
Genomic Testing. PLoS ONE 9(9): e108484. doi:10.1371/journal.pone.0108484
Editor: Vicki Marsh, Kilifi, Kenya
Received June 20, 2014; Accepted August 15, 2014; Published September 26, 2014
Copyright:  2014 McGowan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. Ethical restrictions make data unsuitable for
public deposition. A de-identified data set is available upon request to the corresponding author.
Funding: Support for the preparation of this article was provided by the US National Human Genome Research Institute, Grant NIH R01 HG005277. The funder
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: michelle.mcgowan@case.edu
Introduction
As the cost of genomic analysis has plummeted over the last
decade, genomic risk profiling has become increasingly available
in consumer and clinical settings. In 2007, commercial laborato-
ries began offering consumers products to assess their inherited
risks for a variety of complex diseases and traits by analyzing single
nucleotide polymorphisms (SNPs) across the genome [1]. These
companies ignited a firestorm by making their tests available
directly to consumers (DTC) for purchase via the internet, thereby
disrupting the typical pathway of development and dissemination
for genetic risk information [2]. Critics and regulatory agencies
raised concerns that offering genomic test results DTC with
insufficient knowledge and training in genomics may pose harms
to consumers, the health care system, and society [3–5], as these
tests are non-diagnostic and rarely indicate a clear clinical course
of action [2]. Advocates of DTC genomic risk profiling touted
consumer genomics’ potential to improve the practice of medicine
by empowering patients to independently obtain personal risk
information and then inform their own healthcare through
collaboration with their physicians [6–8]. Yet, research suggests
that general practitioners and genetics specialists alike feel
unprepared to interpret and act on patients’ DTC genomic test
results in their clinical practices – whether because they lack
knowledge, familiarity, or confidence in genomics or because their
skepticism toward commercial testing platforms hinders their
comfort and assuredness in counseling patients on the basis of
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these results [9–16]. As a result, critics argue that ‘‘knowledgable
genetics professionals’’ – employed independently of commercial
laboratories – should be gatekeepers to commercial genomic
testing because ordering, interpreting and returning genomic
information ‘‘requires competent (deliberative, evidence-based,
rigorous, and accountable) clinical judgment’’ [3,17].
In response to regulatory scrutiny, the DTC marketing
approach has faltered [18,19]. Several commercial laboratories
have retreated from selling tests DTC and adopted a more
traditional ‘‘direct-to-provider’’ (DTP) marketing model [1], which
repositions physicians – most often general practitioners – as the
intended recipients of advertising of laboratory services and as
gatekeepers to personal genomic information [4,20]. This shift is
generally attributed to the declining costs of genome sequencing,
the slow uptake of DTC services in the population, and pressures
exerted from the Food and Drug Administration (FDA) and
medical professional societies on the genomics industry to comply
with laboratory and medical device standards [1,21]. Some
laboratories have even taken the stance that if genomic analysis
is to have any impact on how clinicians practice medicine, it will
be through direct relationships with companies rather than
through patients who provide profiles they have personally
acquired [21]. The retreat from the DTC model has been
applauded by those who consider professional clinical judgment
indispensable in the interpretation of results provided by
commercial laboratories [3,22].
As enthusiasm for clinical applications of next generation
sequencing (NGS) grows [23], so does the challenge of
understanding, translating and managing genomic risk assessment.
Clinical sequencing will require not only the ability to interpret
patient data and answer patient questions about specific genomic
risks, but also to address the ‘‘incidentalome’’ of other information
of variable significance that comes with it [24]. In addition,
professional genetics societies are generating growing lists of
genetic mutations that are deemed predictive enough of prevent-
able risks to warrant opportunistic sequencing by laboratories
whenever clinical sequencing is ordered [25]. Meanwhile, even as
the feasibility of clinical sequencing is being studied by the
National Institutes of Health, commercial genomics laboratories
such as Ambry Genetics, DNA DTC, Gene Dx, and Illumina are
now marketing both targeted and whole exome sequencing DTP.
These companies are also promising to convey opportunistic
‘‘secondary’’ sequencing results alongside the requested informa-
tion for physicians to convey to patients as they see fit [26–29].
These factors put a premium on making sure that those who are
charged with interpreting, translating, communicating and man-
aging commercial genomic risk results are appropriately equipped
for the job. Do primary care physicians and other health
professionals who order commercial genomic tests and receive
results have the skills and knowledge necessary to make sound
clinical judgments? If not, where will they obtain that knowledge?
Research suggests that primary care physicians who feel well-
informed about genetic testing are receptive to incorporating
genomic risk profiling into their practices [30], but little is known
about their knowledge of genomics and the factors that contribute
to their decisions to offer genomic testing to patients. To shed light
on these issues, we turn to data from a study of early clinical users
of genomic risk assessment. The perspectives of early-adopting
clinicians are valuable because early adopters are typically defined
by their willingness to promote and adapt technology to suit their
own use and by their contributions to shaping its future use [31].
Given the likelihood that genomic risk assessment tools will be
further integrated into clinical care in the future, it is particularly
important to understand the ideological beliefs, knowledge, and
practices of early adopting clinicians.
Methods
The study was designed to assess how early clinical users of
genomic risk assessment understood genomics and used their
knowledge of genomics to inform clinical decisions. The data
presented here was collected as a component of a larger study
investigating how the goals, benefits, challenges, and consequences
of translational genomic research (TGR) and personalized
genomic medicine (PGM) are interpreted and anticipated by its
proponents. The broader study involved interviews with leaders in
key stakeholder groups [32], such as research funders, scientists,
journal editors, clinicians, educators, and entrepreneurs. Data
presented here are focused on interviews conducted with clinicians
implementing PGM in their practices. This group represented a
distinct vantage point with respect to the clinical translation of
genomic information.
We employed a purposive sampling strategy to identify early
clinical adopters of DTP genomic risk assessment. We first
reviewed the member organizations under ‘‘Consumer Genetic
Testing Services’’ on the Personalized Medicine Coalition website
and visited each organization’s website to determine whether
consumer genetic testing services were accompanied by informa-
tion or services provided by partnering clinicians. Of these, two
commercial genetic testing laboratories indicated that they offered
genomic services to patients through a certified health care
professional.
Hence, our sample was comprised of clinician partners of these
two commercial genetic testing laboratories: DNA Direct, a
commercial laboratory that provides decision support tools and
genetic counseling support to clinicians to help them incorporate
personalized genomic medicine into their clinical practices [33];
and Navigenics, a highly influential but now defunct commercial
laboratory that established collaborative partnerships with con-
cierge physicians to offer SNP-based genomic risk assessment as a
service to their patients [34].
Participants were recruited from 17 clinical sites (16 in the U.S.
and one in Canada) listed as partners on the DNA Direct and
Navigenics websites in 2011 Of the 91 clinicians affiliated with
these sites, 18 clinicians agreed to participate, 37 declined, 23 were
unresponsive, and 13 were determined to be ineligible either
because the recruitment letter was returned as undeliverable or
because the clinician had left the practice. While the response rate
and sample size may be considered limitations of the study, the
response rate is consistent with other studies involving physician
recruitment for qualitative interviews [35] and provided sufficient
data to achieve theoretical saturation [36]. We cannot claim that
the views of respondents are representative of the pool of clinicians
from which they were recruited, but they are demographically
similar to non-respondents in terms of educational attainment and
clinical practice affiliation. The timeframe in which the study was
conducted may also be seen as a limitation of the study as the
commercial genomic testing approach of partnering with clinicians
has expanded since the data was collected in 2011. However, these
data provide a novel set of perspectives of early clinical users of
genomic risk assessment that can be instructive as commercial
genomic testing becomes further integrated into clinical care.
This study was approved by the Case Western Reserve
University IRB (approval number 20100801). Participants pro-
vided oral consent to participate in a phone interview with one of
three study research associates, which was documented in a
password-protected database. Because interviews were conducted
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by phone and for the ease of to obtaining consent in real time, the
IRB approved our request to seek oral consent over written
consent for this study. Once the interviewer turned on the audio
recording device, he or she asked the interviewee whether they
would provide oral consent to participate in the study. The
interviewee’s response was then captured on the interview
recording.
Interviews probed clinician perspectives on and experiences
with partnering with commercial genomics laboratories and
offering genomic risk profiling to their patients (see Appendix S1
for the interview guide). Interviews were conducted by phone,
digitally-recorded and transcribed for thematic analysis. In an
iterative process combining inductive and deductive methods, the
research team used a subset of transcripts to generate a coding
scheme [36]. To enhance inter-coder reliability, the research team
developed a codebook of definitions and examples for each code
and rules for applying codes to the transcripts [37,38], and coded a
batch of initial interviews together to refine codes and coding rules
[39]. Interview transcripts were double-coded by two research
assistants and reviewed for reliability using Atlas.ti 6 qualitative
analytic software. Areas of disagreement were then reviewed to
achieve consensus. The research team drafted summaries of coded
data, working across summaries to identify larger themes [39,40].
Results
We conducted a total of 18 interviews with clinicians affiliated
with 16 clinical sites in the United States and 1 clinical site in
Canada. We interviewed 15 primary care physicians, two genetic
counselors, and one medical geneticist practicing in community
hospitals and private concierge medical practices (where patients
pay a retainer fee for individualized, preventive, and wellness-
oriented health care from a physician with a low patient load) [41].
The clinicians established relationships with the companies to
commission laboratory testing as well as analytic, decision-support,
and genetic counseling services to help interpret laboratory-issued
genomic test result reports [33,34]. These clinicians were not
employed by the commercial laboratories DNA Direct or
Navigenics, and, to our knowledge, did not receive financial
incentives for partnering with these commercial laboratories to
offer genomic risk assessments to patients.
Most interviewees indicated that they first learned about
genomic risk assessment through laboratories’ DTP marketing
campaigns, which were aimed toward what one family physician
characterized as ‘‘physicians that are … looking for more
opportunity [sic] for prevention and wellness’’ (Provider 129).
An internist affiliated with a network of concierge medicine
providers explained that Navigenics approached his practice:
to see if we would be interested in sending, having our
patients genomically tested. So I did a little pilot study to see
how we thought genomic testing might work into our
practice … of 30 patients that [Navigenics] tested for free
whereby either blood or buccal swabs were sent to their lab
and then results sent back on those patients … So it was
interesting and it was expensive. Well it wasn’t expensive for
the patient, ‘cause they were all done for free, but
subsequently it’s expensive to do the genetic testing.
[Navigenics was] gonna give us a special deal because of
our large number of patients throughout the country that
might be interested in this, because generally they’re patients
that are pretty proactive patients that are really caring about
their health and would be willing to be tested for various
types of screening that might benefit them. So it was a
population that was easily captured for [Navigenics].
(Provider 107)
Clinicians affiliated with concierge practices found the oppor-
tunity to offer genomic risk assessment appealing because the
laboratories’ values seemed aligned with their own focus on
personalized, preventive, and wellness-oriented patient care [42].
Other participants were convinced of the overall value of these
services after receiving a discounted or complimentary self-test.
One family physician recommended that all physicians consider-
ing a partnership with a commercial laboratory undergo genomic
risk assessment themselves because ‘‘they can start to understand
personally how it might actually be beneficial for their patients’’
(Provider 156). Some clinicians added that incorporating DTP
genomic risk assessment into their practices helped give them a
competitive edge over other local practices by allowing them to
offer the latest screening technologies. To this end, a genetic
counselor reported that her patients are ‘‘generally expecting …
information about risk, about probability that might help them to
… be more proactive about their health care. … They’re seeking
out these services as one more piece of information that can help
them in that area’’ (Provider 37).
Working with the commercial laboratories was not only seen as
a new way to enhance their relationships with patients, but it also
allowed these clinicians to tap a knowledge base they did not have
or could not otherwise access. As one internist explained, ‘‘I knew
so many things were happening in genetics, and I knew that some
of the tests were hard to order. They were hard to determine
which tests to do, and since I had an interest in preventive
medicine, the idea that someone had put together a profile of
diseases that/where you could do some intervention was great’’
(Provider 131).
Some clinicians characterized DTP genomic risk assessment as
an informational tool that complemented self-reported family
history. Others indicated that it had resulted in increased health
monitoring to promote patient wellness (e.g., annual CT scans for
patients whose results indicated SNPs associated with increased
lung cancer risk). Some also characterized the benefit of DTP
genomic risk assessment as a way to encourage patients to improve
their lifestyles or modify their risk behaviors. For example, one
internist ruminated that ‘‘it is expensive, but it’s helpful to motivate
patients to do lifestyle changes that are difficult, to do different
screenings that might be more appropriate for them than if they
hadn’t known they were at higher risk for that condition’’
(Provider 109). A family physician similarly argued, ‘‘those
[patients] who are getting it done are interested, and [by paying
out of pocket] they’ve got skin in the game financially too’’
(Provider 156).
At the same time, other study participants were skeptical about
the value of partnering with commercial laboratories, character-
izing genomic risk profiling as an add-on connoisseur service that
comes at a high out-of-pocket cost to patients. Citing factors such
as prematurity of the science and evidence of the low return on
investment, some clinicians, like this internist, argued that ‘‘most
doctors and most colleagues I have still don’t see the value of
Navigenics beyond traditional family history and testing we do, the
traditional risk factors’’ (Provider 138). Even some of the
participants who had ordered genomic risk assessments for their
own patients, such as the following internist, were skeptical of the
value of genomic risk profiling in its present form:
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I didn’t feel like it was something strong enough that I could
sell… I don’t think it really impacted my practice, and the
way I felt about it is that it was just too premature of a
science at that point… so I really, I’m like ‘You know what?
Let the science work itself out, and then I’ll revisit it in the
future.’
In sum, even among clinicians who have entered into
relationships with DTP companies and are affiliated with pay-
for-service medical practices, there is a striking divergence of views
about the medical merits of genomic risk assessment services.
The factor participants cited most commonly as a draw for
partnering with commercial laboratories was a knowledge deficit
that most providers willingly admitted: insufficient expertise in
genomics to independently and critically evaluate and interpret
commercial test results, and an inability to help their patients
manage genomic risk susceptibility results. Instead, they needed to
depend almost exclusively on the laboratories from which they
ordered tests. As an internist elaborated:
I have a genetic counselor from Navigenics who’s available
to our patients, but really represents an excellent resource
for me when I have questions. I have access to be able to ask
her questions by email or call her, and so I’m learning on the
job. And I’m far from an expert, but I assume I know more
than most of my primary care colleagues… A deficiency in
moving towards gene-based medicine is that it is difficult to
acquire this information, and particularly with busy primary
care doctors who just hardly have time to keep up with the
usual literature to learn something new. There just isn’t
enough time. (Provider 40)
Virtually all of the information study participants used to
explain genetic risk susceptibilities to patients came directly from
partnering commercial laboratories–through training programs to
familiarize clinicians with commercial products and services, pre-
test advice on the appropriateness of testing, and/or ad hoc
counseling by staff genetic counselors to help clinicians interpret
test results. As two internists explained:
So basically I had a couple of sessions mostly over the
phone, and what [the laboratory] sent me as far as reading
material from Navigenics, talking to the genetic counselors–
there were two that I spoke with–as well as the PhD
geneticist there regarding the technique of the testing and
what the SNPs mean and how to really correlate it, you
know because it’s really sort of a lifetime genetic, lifetime risk
factor you know and how to explain it to the patient.
(Provider 107)
The training was a couple of one-hour PowerPoint
presentations. Then I have frequent conversations (verbally
and email) with my genetic counselor at Navigenics … I’m
able to review the results of most patients, but I use her as a
resource for questions I have prior to presenting it to the
patients. So she’s been a great resource… We [physicians]
cannot keep track of all the basic science - that explosion
that is occurring logarithmically - but Navigenics does ‘cause
I know they update their profiles with each and every major
scientific journal. So we rely on them to update their risk
analysis based on discovery of new genetic sequences and
new risk factors. We rely on them a lot to do that. (Provider
138)
Participants were generally uncritical of and grateful for the
training and information that they received from the commercial
laboratories. In explaining the value of partnering with commer-
cial laboratories by filling a knowledge gap for ordering clinicians,
one family physician explained:
We don’t always have expertise in the field. We don’t know
when to initiate a test. We don’t know how to interpret the
test. We don’t know how to use the information we got to
the patient’s best cause, whereas using the DNA Direct
application allows us to make a determination whether or
not, as clinicians, we should order this test … then the
information comes back to us in a format that we can
understand as clinicians. It doesn’t come back in gobbledy-
gook that we don’t understand. The system gives us access to
a geneticist so that we’re not left like flapping in the breeze
and we’re able to do justice to our community in that we’re
able to educate them on where the personalized medicine is
important. (Provider 114)
The medical geneticist we interviewed justified this approach by
arguing ‘‘[I]t’s just a tool. You don’t even need to understand all
the medicine or all the genetics or whatever. The same way that
we are measuring cholesterol and most people don’t know all the
lipid pathways of biochemistry in order to be able to look at the
values’’ (Provider 38). Finally, in articulating why having resources
provided by the commercial laboratory was so important to
ordering clinicians, a genetic counselor – who presumably would
have more specialized training in genomics than a family physician
or internist - explained:
I feel like I need to be the expert, even though you know
obviously I can’t be an expert in every aspect, and so I feel
that DNA Direct is really my fallback, my support system
and network you know if I have questions about a case or
you know how to follow someone clinically or how to
proceed you know with the testing or whatever. Whatever
questions I have I can always call DNA Direct, talk with a
counselor, get some feedback. Otherwise I think if DNA
Direct weren’t here and it weren’t part of my job, I would
have a lot of difficulty with trying to stay current and have
that support. (Provider 21)
Discussion
Our study suggests that many early-adopting clinical providers
of SNP-based genomic testing were enthusiastic about the
potential for these tests to enhance the personalized, preventive
and wellness orientations of their clinical practices. However, they
largely did not have sufficient knowledge of genomics to
independently help their patients manage the genetic risk
information that commercial genomic analysis could provide.
Instead, clinicians depended on the testing companies themselves
to interpret the data in order to counsel their patients. Thus, the
retreat to DTP marketing and service delivery model – in which
genomic risk assessments are delivered through clinicians to their
patients rather than directly to consumers – cannot guarantee the
provision of adequate expertise to protect patients or ensure sound
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clinical judgment on behalf of health care providers. The debate
over whether companies or clinicians are better equipped to
interpret and counsel the public about the results of commercial
genomic risk tests may therefore be misplaced, as the interpreta-
tions in either delivery model ultimately comes from the same
source. Rather, genetics professionals and policy-makers should
scrutinize the scientific validity and clinical soundness of the
process by which commercial laboratories interpret their own
findings because it is this information that forms the basis of both
clinical and public understanding in both DTC and DTP contexts.
Though commercial genomic risk assessment represents only
one way that genomics has made inroads into clinical practice, it is
often taken for granted that the effective translation of genetics and
genomics into primary care requires clinicians’ knowledge and
training in applied genetics and genomics [15,30,43,44]. Our
results suggest that clinicians do not have the expertise to counsel
patients in this regard, even if they have the interest. Moreover,
previous research with clinicians who use genomic risk profiling
suggests that these clinicians prefer to learn about genomics
through continuing medical education, medical literature, formal
coursework and seminars [30]. However, the clinicians we
interviewed are not gaining knowledge of genomics through these
more impartial sources.
The clinicians we interviewed did not express significant
concern about the arrangement with commercial laboratories, as
it fits with conventional practice regarding the introduction of
other medical technologies. Nevertheless, critics have warned that
genetic counselors affiliated with commercial laboratories may,
more like pharmaceutical representatives than ultrasound techni-
cal support staff, be inappropriately or vulnerably positioned to
educate physicians about new tests and services [4,5]. Commercial
laboratories have a vested interest in maintaining control over
expertise in genomic test development, dissemination, and
interpretation, hence may be a biased source of information for
clinicians about the benefits and drawbacks of tests [45]. Because
clinicians must rely on some other entity for both testing and
interpretation, DTP marketing and the educational practices of
commercial laboratories demand as much regulatory scrutiny as
their DTC initiatives. Neither DTP nor DTC marketing and
service delivery models guarantee adequate end user expertise in
genomic interpretation. This problem is likely to persist in
alternative models too.
Personal genetic information has long been held as exceptional
in the clinical and research sphere, on the grounds that genomic
risk assessment is more complex, varied and uncertain in meaning
than many other tests that clinicians order [46]. Given the
potential individual and familial implications of knowledge of one’s
heritable risks (whether psychosocial or decisional), Evans and
Berg have argued that personal genomic testing should be treated
like other ‘‘complex medical tests with the power to help, harm,
and confuse’’ [17]. The shifting landscape of genomics and the
uncertainty inherent in genomic testing makes results and
interpretation less stable than, say, a cholesterol test or a chest
film to diagnose pneumonia–particularly because the analytic and
clinical validity and clinical utility of commercial genomic tests
have yet to be established and are subject to change as new data
are generated [22,47]. McGuire and colleagues have argued that a
specialized skill set held by genetics professionals may be required
to conduct and return the results of genomic risk assessment [3].
Nevertheless, because primary care providers are likely to receive
inquiries about genomic testing from patients, it is important to
consider the implications of expanded availability of commercial
genomic testing for a wider range of clinicians than traditional
genetics specialists.
Primary care physicians may play an important role in
integrating genomic risk results by combining information from
other diagnostic tools to develop more sensitive treatment plans
and advice on how to manage increased disease risks [47].
However, our interviewees – the majority of which were primary
care providers – did not convey genomic expertise in ways that
demonstrate competent, deliberate, evidence-based clinical judg-
ment in evaluating genomic risks [3]. Rather, the limited genomic
expertise of these clinicians more closely resembles ‘‘interactional
expertise’’ – the ability to master the rhetorical tools of a specialist
domain without practical competence [48]. But clinicians who
only possess interactional expertise are not likely to have sufficient
competence to assess the validity and utility of commercially-
provided risk information. The presumed benefits of having
clinicians control genomic information may be further impeded if,
as we have suggested in our previous work, patients are more
knowledgeable about genomics than their health care providers,
which may diminish the confidence patients have in the advice of
clinicians regarding genomic risk management [2].
Our findings suggest that clinicians find the DTP marketing
model appealing because it offers a new way to enhance
relationships with patients and to tap information they would
not otherwise have in providing preventive care. But the benefits
of the DTP marketing model nonetheless seem weighted toward
laboratories. The strategy provides a steady stream of new users to
generate profit, and it evades some of the regulatory scrutiny of the
DTC model [1] by channeling the information through clinicians
as more traditional laboratory tests.
The danger here is that this clinician-laboratory partnership
model, in which expertise may be interactional, potentially
compromises the integrity of clinical judgment. This is not to
discredit the strengths that clinicians may bring to genomic
counseling, from professional experience and caution to potential
concerns about professional liability. These strengths benefit
patients regardless of the physician’s level of genomic expertise,
and are applicable any time new technologies are making their
way into the clinical encounter. Rather, our goal is to draw
attention to the potential for conflicts of interest that emerge when
commercial laboratories with a profit motive market their tests to
clinicians, and then counsel clinicians on how results should be
interpreted and conveyed. Most of our interviewees seemed to lack
critical reflection on genomic tests and results, and those that did
take a more critical stance typically pointed to the prematurity of
integrating genomic science into the clinical encounter rather than
with the DTP marketing and service delivery model. It appeared
as though participants found it unproblematic to be receiving tests
and advise on how to order and interpret test results from the same
commercial source. It would be naı̈ve to expect clinicians to
develop genomic expertise or critically evaluate all new genomic
technologies. However, these clinicians seemed even less critical of
commercial genomic risk assessment platforms than early DTC
consumers that we interviewed for an earlier study [2], This is
concerning because customers of DTC genomic profiling were
cautioned to be watchful consumers, but critical reflection is
assumed among those holding titles as clinical professionals and
was not what we found among early adopting clinicians. Even if
clinicians desire genomic knowledge, the DTP model of commer-
cial marketing and test dissemination is unlikely to foster
autonomous substantive expertise among clinicians.
Simply routing commercially-generated genomic risk informa-
tion to patients through physicians will not meet the complex
challenges posed by burgeoning markets in consumer and clinical
genomics. To increase competent clinical judgment in genomics
requires a more nuanced understanding of the dynamics of private
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clinical practice, how clinicians learn about new testing modalities,
and the values that undergird clinical integration of genomic
testing. Rather than emphasizing the need for expert interpreta-
tion of genomic test results, the mode of delivery itself requires
further interrogation and regulatory oversight. Because commer-
cial laboratories are the entities with the most ‘‘skin in the game’’
financially, these laboratories are not the most appropriate entities
to hold and control genomic information and its interpretation.
While SNP-based tests are likely to be replaced by NGS platforms
[49], the dependence of clinicians on commercial genomics
laboratories is likely to endure as increasingly complex genomic
information is taken up by clinicians with less enthusiasm or
interest in engaging genomics than the ‘‘early adopters’’ we
interviewed. Regardless of the technological platform, further
deliberation and guidelines from professional societies and federal
oversight of commercial laboratory services is needed to demon-
strate the analytic and clinical validity and clinical utility of
genomic tests. The dependencies inherent in their interactions
with clinicians pose risks to the integrity of clinical judgment and
patient care. Left unattended, these risks will only increase as
genomics is further integrated into clinical care.
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